Safety of osimertinib in EGFR-mutated non-small cell lung cancer
| العنوان: | Safety of osimertinib in EGFR-mutated non-small cell lung cancer |
|---|---|
| المؤلفون: | Andreea Varga, David Planchard, Laura Mezquita |
| المصدر: | Expert Opinion on Drug Safety. 17:1239-1248 |
| بيانات النشر: | Informa UK Limited, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Lung Neoplasms, medicine.drug_class, Antineoplastic Agents, Disease-Free Survival, Piperazines, Tyrosine-kinase inhibitor, 03 medical and health sciences, T790M, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, medicine, Animals, Humans, Pharmacology (medical), Osimertinib, Epidermal growth factor receptor, Lung cancer, Protein Kinase Inhibitors, Acrylamides, Aniline Compounds, integumentary system, biology, Kinase, business.industry, General Medicine, medicine.disease, respiratory tract diseases, ErbB Receptors, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Cancer research, biology.protein, Non small cell, business |
| الوصف: | Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wild-type tissues. Areas covered: Osimertinib use in EGFR-mutated non-small cell lung cancer patients is described, focusing on safety and tolerability from studies supporting its approval. Expert opinion: Osimertinib demonstrated greater efficacy, including CNS activity, compared to chemotherapy, with a manageable safety profile in pretreated T790M+ EGFR-mutated patients, leading to FDA approval in 2015 within record time in the oncology field. However, the therapeutic strategy in the EGFR-mutated population is changing, following the FLAURA study in untreated EGFR-mutated patients, in which osimertinib improved progression-free survival compared to other TKIs, with a similar toxicity profile but a lower serious adverse event rate. In April 2018, the FDA and EMA approved osimertinib as first-line therapy for EGFR-mutated patients. Long-term survival data will ultimately establish the true benefit of upfront versus sequential strategies guided by T790M status. These studies favor osimertinib for tolerability and safety, except for the slightly higher rate of interstitial lung disease, but which was nonetheless manageable. In the coming years, osimertinib will be consolidated as standard therapy in the EGFR population and in naïve and pretreated patients, based on mature survival data and the toxicity profile. |
| تدمد: | 1744-764X 1474-0338 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8f7695d5b3d07ff5749ecdcaeaf179Test https://doi.org/10.1080/14740338.2018.1549222Test |
| رقم الانضمام: | edsair.doi.dedup.....ba8f7695d5b3d07ff5749ecdcaeaf179 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1744764X 14740338 |
|---|